Good morning - Saturday morning session here at the SAPA conference I’m attending. This is Peter Marks, Director of CBER at FDA. He says they are on track to have 150+ gene therapy INDs this year. The last slide about modular cell Tx manufacturing faci

Good morning - Saturday morning session here at the SAPA conference I’m attending. This is Peter Marks, Director of CBER at FDA. He says they are on track to have 150+ gene therapy INDs this year. The last slide about modular cell Tx manufacturing facilities is pretty cool too. pic.twitter.com/UXdhc5E1CO

More From BioPortfolio on "Good morning - Saturday morning session here at the SAPA conference I’m attending. This is Peter Marks, Director of CBER at FDA. He says they are on track to have 150+ gene therapy INDs this year. The last slide about modular cell Tx manufacturing faci"